T CELLS ENGINEERED TO EXPRESS A
DEFINED GAMMA DELTA RECEPTOR (TEGs)
Gadeta developed a new technology platform based on ground breaking discoveries by Prof. Dr. Jürgen Kuball at the University Medical Centre Utrecht (UMCU) in The Netherlands.
γδ Receptors display an enhanced anti-cancer reactivity based on selectively sensing metabolic changes in cancer cells resulting in a broad recognition of both hematological and solid tumors whilst leaving healthy tissue unharmed.
Marcu-Malina V. et al Blood 2011
The first description of the superiority of TEGs above conventional γδT cells.
Sebestyen Z. et al Cell Reports 2016
Development of an unbiased, genome-wide screening method that identified RhoB as a critical mediator of Vγ9Vδ2 TCR activation in tumor cells.
Scheper W. et al Leukemia 2013
Elucidating a crucial role for γδT cells and the γδTCR in controlling leukemia relapse after allo-HSCT. This novel insight solves a long-standing riddle as to why less relapses are observed after CMV infection in the context of allo-HSCT.
Grunder C. et al Blood 2012
Discovery of the broad tumor recognition of TEGs and the CDR3-region as critical determinant